NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Addendum to NICE guideline CG61, Irritable bowel syndrome in adults: Diagnosis and management of irritable bowel syndrome in primary care. London: National Institute for Health and Care Excellence (NICE); 2015 Feb. (NICE guideline, No. CG61.1.)
Addendum to NICE guideline CG61, Irritable bowel syndrome in adults: Diagnosis and management of irritable bowel syndrome in primary care.
Show detailsF.1. Review question 1 (antidepressants)
| Reference | Reason for exclusion |
|---|---|
| Anon (2007) Systematic review on the management of irritable bowel syndrome in the European Union. European Journal of Gastroenterology & Hepatology 19:suppl-37 | Not a systematic review |
| Aursnes I, Gjertsen MK (2008) Common adverse events associated with an SSRI: meta-analysis of early paroxetine data. Pharmacoepidemiology and Drug Safety. 17:707–713 | Meta-analysis did not match protocol: Adverse effects of SSRIs, not used for IBS |
| Bahar RJ, Collins BS et al. (2008) Double-blind placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents. Journal of Pediatrics. 152:685–689 | Population does not match that specified in protocol (Adolescents) |
| Bassett JT, Cash BD (2008) A review of irritable bowel syndrome and an update on therapeutic approaches. Expert Opinion on Pharmacology. 9:1129–1143 | Not a systematic review |
| Boerner D, Eberhardt R, Metz K, and Schick E (1988) Wirksamkeit ind vertraeglichkeit eines antidepressivums beim colon irritablie, Therapiewoche, 38:201–8. | Study not published in English, foreign language publication only. |
| Brandt LJ, Chey WD et al. (2008) An evidence-based position statement on the management of irritable bowel syndrome. American Journal of Gastroenterology. 104:supplS1–S35 | Guidelines |
| Brennan BP, Fogarty KV et al. (2009) Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study. Human Psychopharmacology. 24:423–428 | Study not an RCT; excluded due to other high quality RCT evidence being available for this question |
| Chao G, Zhang S (2013) A meta-analysis of the therapeutic effects of amitriptyline for treating irritable bowel syndrome. Internal Medicine. 52:419–424 | Higher quality systematic review available: all relevant studies included in this review are included in Cochrane review or excluded from review question |
| Ford AC, Talley NJ et al. (2009) Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut. 58:367–378 | Higher quality systematic review available: all relevant studies included in this review are included in Cochrane review or excluded from review question |
| Ford AC, Guyatt GH et al. (2010) Errors in the conduct of systematic reviews of pharmacological interventions for irritable bowel syndrome. American Journal of Gastroenterology. 150:280–288 | Systematic review/ meta-analysis did not match protocol : a systematic review of methods |
| Ford AC, Talley NJ (2012) Irritable bowel syndrome. BMJ (Online). 345:7873 | Not a systematic review |
| Ford AC, Moayyedi P (2010) Meta-analysis: factors affecting placebo response in the irritable bowel syndrome. Alimentary Pharmacology and Therapeutics. 32:144–158 | Systematic review/ meta-analysis did not match protocol :placebo response rates in IBS trials |
| Fortea J, Prior M (2013) Irritable bowel syndrome with constipation: a European-focused systematic literature review of disease burden. Journal of Medical Economics. 16:329–341 | Not a systematic review |
| Ghadir MR, Habibinejad H et al. (2011) Doxepin is more effective than nortriptyline and placebo for the treatment of diarrhoea-predominant irritable bowel syndrome: a randomised triple-blind placebo-controlled trial. Tehran University Medical Journal. 6:352–358 | Study not published in English, foreign language publication only. |
| Gilkin RJ (2005) The spectrum of irritable bowel syndrome: a clinical review. Clinical Therapeutics. 27:1696–1709 | Not a systematic review |
| Iskandar HN, Cassell B et al. (2014) Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease. J Clin Gastroenterol. | Intervention and comparison does not match that specified in protocol: Comparison of IBD and IBS |
| Lai R-M, Cao L-Y et al. (2012) Efficacy and safety of selective serotonin reuptake inhibitor antidepressants in patients with irritable bowel syndrome: a systematic review. World Chinese Journal of Digestology. | Study not published in English, foreign language publication only. |
| Lundberg GD (2008) Evidence that amitriptyline may be effective in treating diarrhoea-predominant irritable bowel syndrome. Medscape Journal of Medicine. 10:132 | Incorrect publication type: Video file |
| Marks DM, Han C et al. (2008) History of depressive and anxiety disorders and paroxetine response in patients with irritable bowel syndrome: post hoc analysis from a placebo-controlled study. Primary Care Companion to the Journal of Clinical Psychiatry. 10:368–375 | Population does not match that specified in protocol : Response to therapy in those with a history of anxiety/depression and those without |
| Masand PS, Pae CU et al. (2009) A double-blind, randomised, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. Psychosomatics. 50:78–86 | Study already included in Cochrane review, which is included in this review. |
| Mayer EA (2008) Clinical practice. Irritable bowel syndrome. NEJM. 358:1692–1699 | Not a systematic review |
| Mozaffari S, Nikfar S et al. (2013) Metabolic and toxicological considerations for the latest drugs used to treat irritable bowel syndrome. Expert Opinion on Drug Metabolism and Toxicology. 9:403–421 | Not a systematic review |
| Myren J, Lovland B, Larssen SE, and Larsen S (1984) Psychopharmacologic drugs in the treatment of the irritable bowel syndrome. A double blind study of the effect of trimipramine, Annales De Gastroenterologie Et D’Hepatologie.,(3):117–23. | Intervention does not match that specified in protocol: comparison of trimipramine doses |
| Olden KW (2012) Targeted therapies for diarrhoea-predominant irritable bowel syndrome. Clinical & Experimental Gastroenterology. 5:69–100 | Not a systematic review |
| Pae C-U, Lee S-J et al. (2013) Atypical antipsychotics as a possible treatment for irritable bowel syndrome. Expert Opinion on Investigational Drugs. 5:565–572 | Not a systematic review |
| Pae CU, Masand PS et al. (2007) Irritable bowel syndrome in psychiatric perspectives: a comprehensive review. International Journal of Clinical Practice. 10:1708–1718 | Not a systematic review |
| Pare P, Bridges R et al. (2007) Recommendations on chronic constipation (including constipation associated with irritable bowel syndrome) treatment. Canadian Journal of Gastroenterology. 2007:suppl :3B–22B | Guidelines: Canadian recommendations |
| Poitras P, Gougeon A et al. (2008) Extra digestive manifestations of irritable bowel syndrome: intolerance to drugs? Digestive Diseases and Sciences. 53:2168–2176 | Intervention and comparison does not match that specified in protocol: Intolerance to drugs in IBS |
| Rahimi R, Nikfar S et al. (2009) Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World Journal of Gastroenterology. 15:1548–1553 | Higher quality systematic review or Cochrane review available: all relevant studies included in Cochrane review or excluded from review |
| Rahimi R, Nikfar S et al. (2008) Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: a meta-analysis of randomized controlled trials. Archives of Medical Sciences. 4:71–76 | Higher quality systematic review or Cochrane review available: all relevant studies included in Cochrane review or excluded from review |
| Saad RJ, Chey WD (2008) Recent developments in the therapy of irritable bowel syndrome. Expert Opinion on Investigational Drugs. 17:117–130 | Not a systematic review |
| Sainsbury A, Ford AC (2011) Review: treatment of irritable bowel syndrome: beyond fiber and antispasmodic agents. Therapeutic Advances in Gastroenterology. 4:115–127 | Not a systematic review |
| Schmulson M, Chang L (2011) Review article: the treatment of functional abdominal bloating and distension. Alimentary Pharmacology and Therapeutics. 33:1071–1086 | Not a systematic review |
| Shah E, Kim S et al. (2012) Evaluation of harm in the pharmacotherapy of irritable bowel syndrome. American Journal of Medicine. 125:381–393 | Higher quality systematic review or Cochrane review available: all relevant studies included in Cochrane review or excluded from review |
| Shekhar C, Whorwell PJ (2009) Emerging drugs for irritable bowel syndrome. Expert Opinion on Emerging Drugs. 14:673–685 | Not a systematic review |
| Smoot LC (2004) GERD, IBS, and IBD: often misunderstood gastrointestinal disorders. Drug Topics. 148:64 | Incorrect publication type: News article |
| Sohn W, Lee OY et al. (2012) Tianeptine vs amitriptyline for the treatment of irritable bowel syndrome with diarrhoea: a multicentre, open-label, non-inferiority, randomized controlled study. Neurogastroenterology & Motility. 24:860–e398 | Intervention does not match that specified in protocol: Drug not in BNF |
| Solati DK, Adibi P et al. (2010) Effects of relaxation and citalopram on severity and frequency of the symptoms of irritable bowel syndrome with diarrhoea predominance. Pakistan Journal of Medical Sciences. 26:88–91 | Intervention does not match that specified in protocol: Relaxation study |
| Spiller R, Aziz Q et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut. 56:1770–1798 | Guidelines |
| Spinelli A (2007) Irritable bowel syndrome. Clinical Drug Investigation. 27:15–33 | Not a systematic review |
| Storr MM, Andrews CN (2008) Medical management of irritable bowel syndrome in 2008: current and future directions. Canadian Journal of Gastroenterology. 8:673–675 | Incorrect publication type: Expert opinion |
| Szkotak J, Shek A (2012) An evidence-based review of treatment options for irritable bowel syndrome. Formulary 47. 9:319 | Not a systematic review |
| Tack J, Broekaert D et al. (2006) A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut. 55:1095–1103 | Study already included in Cochrane review, which is included in this review. |
| Talley NJ, Kellow JE et al. (2008) Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind randomized, placebo-controlled trial. Digestive Diseases & Sciences. 53:108–115 | Study already included in Cochrane review, which is included in this review. |
| Talley NJ (2008) Newer antidepressants in irritable bowel syndrome: what is the evidence? Archives in Medical Sciences. 4:77–78 | Incorrect publication type: Commentary |
| Trindade E, Menon D et al. (1998) Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ. 159:1245–1252 | Higher quality systematic review or Cochrane review available |
| Trinkley KE, Nahata MC (2011) Treatment of irritable bowel syndrome. Journal of Clinical Pharmacy & Therapeutics. 36:275–282 | Not a systematic review |
| Vahedi H, Merat S et al. (2005) The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. Aliment Pharmacol Ther. 22:381–385 | Study already included in Cochrane review, which is included in this review. |
| Vahedi H, Merat S et al. (2008) Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. 27:678–684 | Study already included in Cochrane review, which is included in this review. |
| van Kerkhoven LAS, Laheij RJF et al. (2007) The role of selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut. 5:733 | Incorrect publication type: Letter |
| van Nieuwenhoven MA, Kilkens TO (2012) The effect of acute serotonergic modulation on rectal motor function in diarrhoea-predominant irritable bowel syndrome and healthy controls. European Journal of Gastroenterology & Hepatology. 24:1259–1265 | Intervention does not match that specified in protocol: Not antidepressants |
| Wang X-Y, Feng Y-G et al. (2011) Efficacy and safety of low-dose tricyclic antidepressants in patients with irritable bowel syndrome: a meta-analysis. World Chinese Journal of Digestology. 19:3458–3463 | Study not published in English, foreign language publication only. |
| Studies included in CG61 (not in 2007 Cochrane review) | |
| Creed F, Fernandes L et al. (2003) The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology. 124:303–17 |
Comparison does not match that specified in protocol: comparison group received usual care, not stated whether they received other pharmacological treatments in addition to usual care. (previously included in CG61) |
| Kuiken SD, Tytgat GN et al. (2003) The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clinical Gastroentrology and Hepatology. 1:21.9–228 | Study already included in Cochrane review, which is included in this review. |
| Steinhart MJ, Wong PY et al. (1982) Therapeutic usefulness of amitriptyline in spastic colon syndrome. International Journal of Psychiatry in Medicine. 11:45–47 | Outcomes not reported in a manner that allows extraction: No scale used for symptom score |
| Tabas G, Beaves M et al. (2004) Paroxetine to treat irritable bowel syndrome not responding to high-fibre diet: a double-blind, placebo-controlled trial. American Journal of Gastroenterology. 99:914–20 | Study already included in Cochrane review, which is included in this review. |
| Tanum L, Malt UF (1996) A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo-controlled study with mianserin. Scandinavian Journal of Gastroenterology. 31:318–25 | Population does not match that specified in protocol: Only 60% of participants had IBS |
| Shrivastava RK and Siegel H (1984) The role of tricyclics and benzodiazepine compounds in the treatment of irritable gut syndrome and peptic ulcer disease. Psychopharmacology Bulletin. 20:616–21 | Population does not match that specified in protocol: Included children, participants with peptic ulcer and IBS |
| Tripathi BM, Misra NP et al. (1983) Evaluation of tricyclic compound (Trimipramine) vis-à-vis placebo in irritable bowel syndrome. Journal of the Association of Physicians of India. 31:201–3 | Population does not match that specified in protocol: Included children, participants with peptic ulcer and IBS |
F.2. Review question 1 (antidepressants), economic studies
| Reference | Reason for exclusion |
|---|---|
| Ljotsson B (2011) Acceptability, effectiveness, and cost-effectiveness of internet-based exposure treatment for irritable bowel syndrome in a clinical sample: a randomized controlled trial. BMC Gastroenterology 11:110 | Irrelevant intervention for this question (not antidepressants) |
| Creed F, Fernandes L, Guthrie E et al. (2003) The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 124: 303–17. | Included in 2008 guideline |
| Fedorak RN, Vanner SJ, Paterson WG et al. (2012) Canadian Digestive Health Foundation Public Impact Series 3: Irritable bowel syndrome in Canada. Incidence, prevalence, and direct and indirect economic impact. Canadian Journal of Gastroenterology.26 (5) (pp 252–256), 2012.Date of Publication: May 2012. 252–6. | Burden of disease analysis |
| Fortea J, Prior M (2013) Irritable bowel syndrome with constipation: A European-focused systematic literature review of disease burden. Journal of Medical Economics.16 (3) (pp 329–341), 2013.Date of Publication: 2013. 329–41. | Burden of disease analysis |
| Hillila MT, Frkkila NJ, Farkkil MA (2010) Societal costs for irritable bowel syndrome a population based study. Scandinavian Journal of Gastroenterology.45 (5) (pp 582–591), 2010.Date of Publication: May 2010. 582–91. | Burden of disease analysis |
| Mapel DW (2013) Functional disorders of the gastrointestinal tract: Cost effectiveness review. Best Practice and Research: Clinical Gastroenterology.27 (6) (pp 913–931), 2013.Date of Publication: December 2013. 913–31. | Commentary only on a wide range of gastrointestinal disorders. i.e. Not an economic evaluation. |
F.3. Review question 2 (low FODMAP diet)
| Reference | Reason for exclusion |
|---|---|
| Barrett JS, Gibson PR (2010) Development and validation of a comprehensive semi-quantitative food frequency questionnaire that includes FODMAP intake and glycaemic index. J Am Diet Assoc. 110:1469–1476 | Incorrect publication type: Questionnaire validation |
| Barrett JS, Gearry RB et al. (2010) Dietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon. Aliment Pharmacol Ther. 31:874–882 | Population does not match that specified in protocol: Participants had ileostomies |
| Barrett JS (2013) Extending our knowledge of fermentable, short-chain carbohydrates for managing gastrointestinal symptoms. Nutrition in Clinical Practice. 28:261–268 | Not a systematic review |
| Barrett JS, Gibson PR (2012) Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and nonallergic food intolerance: FODMAPs or food chemicals? Therap Adv Gastroenterol. 5:261–268 | Not a systematic review |
| de Roest RH, Dobbs BR et al. The low FODMAP diet improves gastrointestinal symptoms in patients with irritable bowel syndrome: a prospective study. Int J Clin Pract. 67:895–903 | Study not an RCT; excluded due to other high quality RCT evidence being available for this question |
| Fedewa A, Rao SS (2014) Dietary fructose intolerance, fructan intolerance and FODMAPs. Curr Gastroenterol Rep. 16:370 | Not a systematic review |
| Gibson PR, Shepherd SJ (2010) Evidence-based dietary management of functional gastrointestinal symptoms: the FODMAP approach. Journal of Gastroenterology & Hepatology. 25:252–258 | Not a systematic review |
| Marcason W (2012) What is the FODMAP diet? J Acad Nutr Diet. 112:1696 | Incorrect publication type: Description of the diet |
| Muir JG, Gibson PR (2013) The low FODMAP diet for treatment of irritable bowel syndrome and other gastrointestinal disorders. Gastroenterol Hepatol. | Incorrect publication type: Expert opinion |
| Olesen M, Gummand-Hoyer E (2000) Efficacy, safety, and tolerability of fructooligosaccharides in the treatment of irritable bowel syndrome. American Journal of Clinical Nutrition. 72:1570–1575 | Intervention does not match that specified in protocol: Not low FODMAP, fructooligosaccharide compared with placebo |
| Ong DK, Mitchell SB et al. (2010) Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. Journal of Gastroenterology & Hepatology. 25:1366–1373 | Only 2 days of dietary intervention which was judged to be insufficient. See protocol footnote. |
| Rangnekar AS, Chey WD (2009) The FODMAP diet for irritable bowel syndrome: food fad or roadmap to a new treatment paradigm? Gastroenterology. 36:37–46 | Incorrect publication type: Study summary |
| Reggie TJ, Nanda R et al. (2012) A FODMAP diet update: craze or credible? Practical Gastroenterology. 2012:37–46 | Not a systematic review |
| Shepherd SJ, Parker FC et al. (2008) Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomised placebo controlled evidence. Clin Gastroenterol Hepatol. 6:765–771 | Intervention does not match that specified in protocol: Baseline of responders to low FODMAP, not low FODMAP compared with other diets |
| Staudacher HM, Irving PM et al. (2014) Mechanisms and efficacy of dietary FODMAP restriction in IBS. Nat Rev Gastroenterol Hepatol. | Not a systematic review |
F.4. Review question 3 (linaclotide)
| Reference | Reason for exclusion |
|---|---|
| Andresen V, Camilleri M et al. (2007) Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 133(3) p 761–768 | Insufficient sample size (n=12 per arm) and follow up period (5 days) which was judged to be insufficient. |
| Atluri DK, Chandar AK, Bharucha AE, Falck-Ytter Y. (2014) Effect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a systematic review and meta-analysis. Neurogastroenterology and Motility. 26 p 499–509. | Meta-analysis did not report study detail of interest in sufficient detail, therefore individual papers included in review.. |
| Casey T (2013) Linaclotide improves abdominal and bowel symptoms. Annals of Long-Term Care. 21(8) p20) | Not a systematic review: not original research |
| Rao SS, Quigley EM et al. (2014) Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation. Clinical Gastroeneterology and Hepatology. 12:616–623. | Duplication of study already included: Sub-population of earlier study. No additional outcomes. |
| Thomas RH and Allmond K. (2013) Linaclotide (Linzess) for irritable bowel syndrome with constipation and for chronic idiopathic constipation. Pharmacy and Therapeutics 38 (3) p154–160. | Incorrect publication type: Drug Forecast/ review |
| Wensel TM and Luthin DR. (2011) Linaclotide: a novel approach to the treatment of irritable bowel syndrome. Annals of Pharmacotherapy 45(12) p1535–1543. | Not a systematic review |
| Videlock EJ, Cheng V et al. (2013) Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis. Clinical Gastroenterology and Hepatology. 11(9) p1084–1092. | Meta-analysis did not report study detail and outcomes of interest in sufficient detail, therefore individual papers included in review. |
F.5. Review question 4 (lubiprostone)
| Reference | Reason for exclusion |
|---|---|
| Anon (2005) Lubiprostone: RU 0211, SPI 0211. [Review] [9 refs]. Drugs in R & D 6: 245–8. | Not a systematic review: Not a primary study. |
| Chey WD, Drossman DA, Johanson JF et al. (2012) Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment.Pharmacol.Ther 35: 587–99. | Study not an RCT; excluded due to other high quality RCT evidence being available for this question: Open labelled study. No comparison with placebo. |
| Fukudo S, Hongo M, Kaneko H et al. (2011) Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study. Neurogastroenterology & Motility 23: 544–e205. | Sample size of study too small: Numbers in IBS-C subgroup too small to enable accurate interpretation of results. |
F.6. Review question 5a (relaxation therapy)
| Reference | Reason for exclusion |
|---|---|
| Acosta RD, Cash BD. Existing and emerging therapies for irritable bowel syndrome. Expert Opinion on Emerging Drugs 16 (2) (pp 389–402), 2011 Date of Publication: June 2011 2011;(2):389–402 | Not a systematic review |
| Bassett JT, Cash BD. A review of irritable bowel syndrome and an update on therapeutic approaches. Expert Opinion on Pharmacotherapy 9 (7) (pp 1129–1143), 2008 Date of Publication: May 2008 2008;(7):1129–1143 | Not a systematic review |
| Blanchard EB, Greene BA, Scharff L, Schwarz-McMorris S. Relaxation Training as a Treatment for Irritable Bowel Syndrome. Biofeedback and Self- Regulation 18[3], 125–132. 1993. | Study reported as an RCT but breaks randomisation, therefore not considered an RCT and excluded from review. Study was included in CG61. |
| Boye B, Lundin KE, Jantschek G, Leganger S, Mokleby K, Tangen T et al. INSPIRE study: does stress management improve the course of inflammatory bowel disease and disease-specific quality of life in distressed patients with ulcerative colitis or Crohn’s disease? A randomized controlled trial. Inflammatory Bowel Diseases 2011; 17(9):1863–1873 | Intervention does not match that specified in protocol: Relaxation as part of a psychotherapy programme, unable to assess the relaxation element |
| De WN, Zijdenbosch I, Van Der Heijden G, Quartero O, Rubin G. Psychological treatments for the management of irritable bowel syndrome. Cochrane Database of Systematic Reviews 2007;(2) | Systematic review did not match protocol: Cochrane review, not all interventions are relaxation |
| Dehkordy, S.,Adibi, P &Gharamaleky, S Effects of relaxation and citalopram in severity and frequency of the symptoms of irritable bowel syndrome with diarrhea predominance. Pakistani Journal of Medical science 2010; 26(1); 88–91. | Study not an RCT: Insufficient detail to indicate that this is a randomised controlled trial. Excluded due to other high quality RCT evidence being available for this question |
| Dobbin A, Dobbin J, Ross SC, Graham C, Ford MJ. Randomised controlled trial of brief intervention with biofeedback and hypnotherapy in patients with refractory irritable bowel syndrome. Journal of the Royal College of Physicians of Edinburgh 43 (1) (pp 15–23), 2013 Date of Publication: 2013 2013;(1):15–23 | Intervention does not match that specified in protocol: biofeedback and hypnotherapy |
| Dorn SD. Systematic review: self-management support interventions for irritable bowel syndrome. [Review]. Alimentary Pharmacology & Therapeutics 2010; 32(4):513–521 | Systematic review did not match protocol: did not include papers with relaxation alone, always as part of a multi-modal approach |
| Drossman D, Morris CB, Hu Y, Toner BB, Diamant N, Whitehead WE et al. Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment. American Journal of Gastroenterology 2007; 102(7):1442–1453 | Incorrect publication type: Study testing the value of IBS QoL questionnaires |
| Enck P, Junne F, Klosterhalfen S, Zipfel S, Martens U. Therapy options in irritable bowel syndrome. [Review]. European Journal of Gastroenterology & Hepatology 2010; 22(12):1402–1411 | Meta-analysis did not match protocol: Meta-analysis of many different treatments for IBS. |
| Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. [Review] [71 refs]. Gut 2009; 58(3):367–378 | Systematic review/ meta-analysis did not report study detail in sufficient detail, relevant individual papers from publication included in review |
| Ford AC, Talley NJ. Irritable bowel syndrome. BMJ (Online) 345 (7873), 2012 Article Number: e5836 Date of Publication: 08 Sep 2012 2012;(Online) | Not a systematic review; overview of current treatment options for IBS. |
| Halland M, Talley NJ. New treatments for IBS. Nature Reviews Gastroenterology and Hepatology 10 (1) (pp 13–23), 2013 Date of Publication: January 2013 2013;(1):13–23. Ref ID: 1819 | Not a systematic review |
| Kearney DJ, Brown-Chang J. Complementary and alternative medicine for IBS in adults: mind-body interventions. [Review] [101 refs]. Nature Clinical Practice Gastroenterology & Hepatology 2008; 5(11):624–636 | Not a systematic review; relaxation as part of a multi-modal approach. |
| Keefer L, Blanchard EB. The effects of relaxation response meditation on the symptoms of irritable bowel syndrome: results of a controlled treatment study. Behaviour Research & Therapy 39, 801–811. 2001. |
Extremely serious risk of bias in study design: Randomisation very unclear; states matched pairs randomised, n<10, very high risk of bias. Included in CG61 |
| Sinagra E, Romano C, Cottone M. Psychopharmacological treatment and psychological interventions in irritable bowel syndrome. Gastroenterology Research and Practice 2012;, 2012. Article Number: 486067. Date of Publication: 2012 | Not a systematic review |
| Van der Veek PP, van Rood YR, Masclee AA. Clinical trial: short- and long-term benefit of relaxation training for irritable bowel syndrome. Alimentary Pharmacology & Therapeutics 2007; 26(6):943–952 | Reported as an RCT but breaks randomisation, therefore not considered an RCT and excluded from review: If people from intervention group dropped out, the participants were allowed to cross over from control to intervention group during study period to replace the dropouts. Lack of detail about when and how many occurences of this. |
| Yoon SL, Grundmann O, Koepp L, Farrell L. Management of irritable bowel syndrome (IBS) in adults: conventional and complementary/alternative approaches. [Review]. Alternative Medicine Review 2011; 16(2):134–151 | Not a systematic review |
| Zernicke KA, Campbell TS, Blustein PK, Fung TS, Johnson JA, Bacon SL et al. Mindfulness-based stress reduction for the treatment of irritable bowel syndrome symptoms: A randomized wait-list controlled trial. [References]. International Journal of Behavioral Medicine 2013; 20(3):385–396 | Intervention does not match that specified in protocol: mindfulness |
F.7. Review question 5a (relaxation therapies), economic studies
| Reference | Reason for exclusion |
|---|---|
| Ahl A, Mikocka-Walus A, Gordon A et al. (2013) Are self-administered or minimal therapist contact psychotherapies an effective treatment for irritable bowel syndrome (IBS): A systematic review. Journal of Psychosomatic Research.75 (2) (pp 113–120), 2013.Date of Publication: August 2013. 113–20. | Not an economic evaluation |
| Andersson E, Ljotsson B, Smit F et al. (2011) Cost-effectiveness of internet-based cognitive behavior therapy for irritable bowel syndrome: results from a randomized controlled trial. BMC Public Health 11: 215. | Irrelevant intervention for this question (not relaxation therapy) |
| Camilleri M (2000) Economic burden of irritable bowel syndrome: proposed strategies to control expenditures. PharmacoEconomics 17(4):331–338 | Burden of disease analysis |
| Creed F (2003) The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 124(2):303–317 | Included in previous guideline |
| Gilkin J (2005) The spectrum of irritable bowel syndrome: A clinical review. Clinical Therapeutics.27 (11) (pp 1696–1709), 2005.Date of Publication: November 2005. 1696–709. | Burden of disease analysis |
| Hedman E, Ljotsson B, Lindefors N (2012) Cognitive behavior therapy via the Internet: a systematic review of applications, clinical efficacy and cost-effectiveness. [Review]. Expert Review of Pharmacoeconomics & Outcomes Research 12: 745–64. | Irrelevant intervention (not relaxation therapy) |
| Kennedy TM, Chalder T, McCrone P et al. (2006) Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: Randomised controlled trial. Health Technology Assessment.10 (19) (pp iii–48), 2006.Date of Publication: June 2006. iii–48. | Irrelevant intervention (not relaxation therapy) |
| Lee V, Guthrie E, Robinson A et al. (2008) Functional bowel disorders in primary care: Factors associated with health-related quality of life and doctor consultation. Journal of Psychosomatic Research.64 (2) (pp 129–138), 2008.Date of Publication: February 2008. 129–38. | Not an economic evaluation |
| Ljotsson B, Andersson G, Andersson E et al. (2011) Acceptability, effectiveness, and cost-effectiveness of internet-based exposure treatment for irritable bowel syndrome in a clinical sample: a randomized controlled trial. BMC Gastroenterology 11: 110. | Irrelevant intervention for this question (not relaxation therapy) |
| McCrone P, Knapp M, Kennedy T et al. (2008) Cost-effectiveness of cognitive behaviour therapy in addition to mebeverine for irritable bowel syndrome. European Journal of Gastroenterology & Hepatology 20: 255–63. | Irrelevant intervention (not relaxation therapy) |
| Muller-Lissner SA (2002) Irritable bowel syndrome in Germany. A cost of illness study. European Journal of Gastroenterology and Hepatology 14:1325–1329 | Burden of disease analysis |
| van der Veek PP, van Rood YR, Masclee AA (2007) Clinical trial: short- and long-term benefit of relaxation training for irritable bowel syndrome. Alimentary Pharmacology & Therapeutics 26: 943–52. | Not an economic evaluation |
| Van Tilburg MAL, Palsson OS, Levy RL et al. (2008) Complementary and alternative medicine use and cost in functional bowel disorders: A six month prospective study in a large HMO. BMC Complementary and Alternative Medicine.8, 2008.Article Number: 46.Date of Publication: 24 Jul 2008. | Burden of disease analysis |
| Zijdenbos IL, de Wit NJ, van der Heijden GJ et al. (2009) Psychological treatments for the management of irritable bowel syndrome. [Review] [111 refs]. Cochrane Database of Systematic Reviews : CD006442. | No economic outcomes |
F.8. Review question 5b (CCBT and Mindfulness therapy)
| Reference | Reason for exclusion |
|---|---|
| Ahl A, Mikocka-Walus A, Gordon A et al. (2013) Are self-administered or minimal therapist contact psychotherapies an effective treatment for irritable bowel syndrome (IBS): a systematic review. [Review]. Journal of Psychosomatic Research 75: 113–20. | Systematic review did not report study detail in sufficient detail, therefore individual papers included in review: used as cross checking. |
| Barabasz A, Barabasz M (2006) Effects of tailored and manualized hypnotic inductions for complicated irritable bowel syndrome patients. International Journal of Clinical & Experimental Hypnosis 54: 100–12. | Intervention does not match that specified in protocol: Hypnotherapy |
| Berrill JW, Sadlier M, Hood K et al. (2014) Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. J Crohns Colitis | Population does not match that specified in protocol: IBD population, not IBS. |
| Blanchard EB, Lackner JM, Sanders K et al. (2007) A controlled evaluation of group cognitive therapy in the treatment of irritable bowel syndrome. Behaviour Research & Therapy 45: 633–48. | Intervention does not match that specified in protocol: CBT only (not CCBT) |
| Blanchard EB, Lackner JM, Sanders K et al. (2007) A controlled evaluation of group cognitive therapy in the treatment of irritable bowel syndrome. [References]. Behaviour Research and Therapy 45: 633–48. | Intervention does not match that specified in protocol: CBT only (not CCBT) |
| Brotto LA (2012) Mindfulness training reduces the severity of irritable bowel syndrome in women: Results of a randomized controlled trial. Journal of Sexual Medicine 9: 967–8. | Incorrect publication type: review of the Gaylord (2011) paper. |
| Cash BD (2009) Review: Antidepressants and psychological therapies improve symptoms of irritable bowel syndrome. Evidence-Based Medicine.14 (4) (pp 119), 2009.Date of Publication: August 2009. | Incorrect publication type: Abstract only. |
| Craske MG, Wolitzky-Taylor KB, Labus J et al. (2011) A cognitive-behavioral treatment for irritable bowel syndrome using interoceptive exposure to visceral sensations. Behaviour Research & Therapy 49: 413–21. | Intervention does not match that specified in protocol: CBT only (not CCBT) |
| Creed F, Fernandes L, Guthrie E et al. (2003) The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 124: 303–17. | Intervention does not match that specified in protocol: Psychotherapy and already included in the original guideline 2007. |
| Creed F, Tomenson B, Guthrie E et al. (2008) The relationship between somatisation and outcome in patients with severe irritable bowel syndrome. Journal of Psychosomatic Research 64: 613–20. | Incorrect publication type: not about treatment efficacy or effectiveness. |
| Deechakawan W, Cain KC, Jarrett ME et al. (2013) Effect of self-management intervention on cortisol and daily stress levels in irritable bowel syndrome. Biological Research for Nursing 15: 26–36. | Intervention does not match that specified in protocol. |
| Deechakawan WI (2011) Effect of a comprehensive self-management intervention on urine cortisol/catecholamine levels and daily stress/emotional symptoms in adults with Irritable Bowel Syndrome. Dissertation Abstracts International: Section B: The Sciences and Engineering 72: 2030. | Intervention does not match that specified in protocol. |
| Dobbin A, Dobbin J, Ross SC et al. (2013) Randomised controlled trial of brief intervention with biofeedback and hypnotherapy in patients with refractory irritable bowel syndrome. Journal of the Royal College of Physicians of Edinburgh 43: 15–23. | Intervention does not match that specified in protocol: Hypnotherapy and biofeedback |
| Dorn SD (2010) Systematic review: self-management support interventions for irritable bowel syndrome. [Review]. Alimentary Pharmacology & Therapeutics 32: 513–21. | Systematic review did not match protocol: Included other interventions that were not covered by the update remit – used as cross checking. |
| Drossman DA, Toner BB, Whitehead WE et al. (2003) Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 125: 19–31. | Intervention does not match that specified in protocol: CBT only (not CCBT), included in the original guideline 2007. |
| Everitt H, Moss-Morris R, Sibelli A et al. (2013) Management of irritable bowel syndrome in primary care: The results of an exploratory randomised controlled trial of mebeverine, methylcellulose, placebo and a self-management website. BMC Gastroenterology.13 (1), 2013.Article Number: 68.Date of Publication: 21 Apr 2013. | Outcomes not reported in a manner that allows extraction: A 3x3 design with various combinations of different drugs and CCBT, the data was analysed in combination – unable to extract data from each arm under each intervention. |
| Everitt HA, Moss-Morris RE, Sibelli A et al. (2010) Management of irritable bowel syndrome in primary care: feasibility randomised controlled trial of mebeverine, methylcellulose, placebo and a patient self-management cognitive behavioural therapy website. (MIBS trial). BMC Gastroenterology 10: 136. | Incorrect publication type: Research protocol only. |
| Fernandez C, Amigo I (2006) Efficacy of training in stress and contingency management in cases of irritable bowel syndrome. Stress and Health.22 (5) (pp 285–295), 2006.Date of Publication: December 2006. | Intervention does not match that specified in protocol. Included in different section of the the original guideline 2007. |
| Fernandez C, Perez M, Amigo I et al. (1998) Stress and contingency management in the treatment of irritable bowel syndrome. Stress Medicine 14: 31–42. |
Intervention does not match that specified in protocol. Included in different section of the the original guideline 2007. |
| Fjorback LO, Arendt M, Ornbol E et al. (2013) Mindfulness therapy for somatization disorder and functional somatic syndromes: randomized trial with one-year follow-up. Journal of Psychosomatic Research 74: 31–40. | Population does not match that specified in protocol: Not IBS population. |
| Flik CE, van Rood YR, Laan W et al. (2011) A randomised controlled trial on hypnotherapy for irritable bowel syndrome: design and methodological challenges (the IMAGINE study). BMC Gastroenterology 11: 137. | Intervention does not match that specified in protocol: Hypnotherapy |
| Forbes A, MacAuley S, Chiotakakou-Faliakou E (2000) Hypnotherapy and therapeutic audiotape: effective in previously unsuccessfully treated irritable bowel syndrome? International Journal of Colorectal Disease 15: 328–34. |
Intervention does not match that specified in protocol. Included in different section of the the original guideline 2007. |
| Ford AC, Talley NJ, Schoenfeld PS et al. (2009) Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. [Review] [71 refs]. Gut 58: 367–78. | Systematic review did not match protocol: Included other interventions that were not covered by the update remit – used as cross checking. |
| Ford AC, Talley NJ, Schoenfeld PS et al. (2009) Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis (Structured abstract). Gut 58: 367–78. | Duplication of study already included |
| Gaylord S, Palsson OS, Garland E et al. (2011) Therapeutic impact of mindfulness meditation on Irritable Bowel Syndrome (IBS): Results of a randomized controlled trial [conference abstract]. Gastroenterology [abstracts from Digestive Disease Week, DDW 2011 Chicago, IL United States.May 7–10] 140 | Incorrect publication type: Abstract only. |
| Gaylord SA, Whitehead WE, Coble RS et al. (2009) Mindfulness for irritable bowel syndrome: protocol development for a controlled clinical trial. BMC Complementary & Alternative Medicine 9: 24. | Incorrect publication type: Research protocol only. |
| Gerson CD, Gerson J, Gerson MJ (2013) Group hypnotherapy for irritable bowel syndrome with long-term follow-up. International Journal of Clinical & Experimental Hypnosis 61: 38–54. | Intervention does not match that specified in protocol: Hypnotherapy |
| Gholamrezaei A, Ardestani SK, Emami MH (2006) Where does hypnotherapy stand in the management of irritable bowel syndrome? A systematic review. [Review] [48 refs]. Journal of Alternative & Complementary Medicine 12: 517–27. | Intervention does not match that specified in protocol: Hypnotherapy |
| Grundmann O, Yoon SL (2013) Mind-body therapies for functional bowel disorders-A review of recent clinical trials. European Journal of Integrative Medicine.5 (4) (pp 296–307), 2013.Date of Publication: August 2013. | Population does not match that specified in protocol: Population of functional bowel disorders, unable to extract subgroup data for IBS population. |
| Haghayegh SA, Kalantari M, Molavi H et al. (2011) The efficacy of cognitive-behavior group therapy on health-related quality of life, health anxiety and depression in patients with diarrhea-predominant irritable bowel syndrome. Pakistan journal of medical sciences 27: 749–53. | Intervention does not match that specified in protocol: CBT only (not CCBT) |
| Jarrett ME, Cain KC, Burr RL et al. (2009) Comprehensive self-management for irritable bowel syndrome: randomized trial of in-person vs. combined in-person and telephone sessions. American Journal of Gastroenterology 104: 3004–14. | Intervention does not match that specified in protocol: |
| Kafi M, Afshar H, Moghtadaei K et al. (2014) Effectiveness of mindfulness-based cognitive-therapy on psychological signs women with irritable bowel syndrome. Koomesh 15: 255–64. | Study not published in English, foreign language publication only. |
| Kennedy T, Jones R, Darnley S et al. (2005) Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial. BMJ 331: 435. |
Intervention does not match that specified in protocol: CBT only (not CCBT) Included in different section of the the original guideline 2007. |
| Labus J, Gupta A, Gill HK et al. (2013) Randomised clinical trial: symptoms of the irritable bowel syndrome are improved by a psycho-education group intervention. Alimentary Pharmacology & Therapeutics 37: 304–15. | Intervention does not match that specified in protocol: Psychoeducation |
| Lackner JM, Jaccard J, Krasner SS et al. (2007) How does cognitive behavior therapy for irritable bowel syndrome work? A mediational analysis of a randomized clinical trial. Gastroenterology 133: 433–44. | Study type does not match that specified in protocol: Not a comparative study. |
| Lackner JM, Jaccard J, Krasner SS et al. (2008) Self-administered cognitive behavior therapy for moderate to severe irritable bowel syndrome: clinical efficacy, tolerability, feasibility. Clinical Gastroenterology & Hepatology 6: 899–906. | Intervention does not match that specified in protocol: CBT only (not CCBT) |
| Lackner JM, Gudleski GD, Keefer L et al. (2010) Rapid response to cognitive behavior therapy predicts treatment outcome in patients with irritable bowel syndrome. Clinical Gastroenterology & Hepatology 8: 426–32. | Intervention does not match that specified in protocol: CBT only (not CCBT) |
| Lackner JM, Keefer L, Jaccard J et al. (2012) The Irritable Bowel Syndrome Outcome Study (IBSOS): rationale and design of a randomized, placebo-controlled trial with 12 month follow up of self-versus clinician-administered CBT for moderate to severe irritable bowel syndrome. Contemporary Clinical Trials 33: 1293–310. | Incorrect publication type: Research protocol only |
| Lee HH, Choi YY, Choi M-G (2014) The efficacy of hypnotherapy in the treatment of irritable bowel syndrome: A systematic review and meta-analysis. Journal of Neurogastroenterology and Motility.20 (2) (pp 152–162), 2014.Date of Publication: 2014. | Intervention does not match that specified in protocol: Hypnotherapy |
| Lindfors P, Unge P, Arvidsson P et al. (2012) Effects of gut-directed hypnotherapy on IBS in different clinical settings-results from two randomized, controlled trials. American Journal of Gastroenterology 107: 276–85. | Intervention does not match that specified in protocol: Hypnotherapy covered by the update remit. |
| Lindfors P, Ljotsson B, Bjornsson E et al. (2013) Patient satisfaction after gut-directed hypnotherapy in irritable bowel syndrome. Neurogastroenterology & Motility 25: 169–e86. | Study type does not match that specified in protocol: Qualitative study, |
| Ljotsson B, Andreewitch S, Hedman E et al. (2010) Exposure and mindfulness based therapy for irritable bowel syndrome-an open pilot study. Journal of Behavior Therapy & Experimental Psychiatry 41: 185–90. | Study type does not match that specified in protocol: before and after study. |
| Ljotsson B, Hesser H, Andersson E et al. (2013) Mechanisms of change in an exposure-based treatment for irritable bowel syndrome. Journal of Consulting & Clinical Psychology 81: 1113–26. | Study type does not match that specified in protocol: Not RCT, not a comparative study of effectiveness. |
| Ljotsson B, Lindfors P, Lackner JM et al. (2013) Prediction of symptomatic improvement after exposure-based treatment for irritable bowel syndrome. BMC Gastroenterology.13 (1), 2013.Article Number: 160.Date of Publication: 19 Nov 2013. | Study type does not match that specified in protocol: Not a comparative study. |
| Ljotsson B, Hedman E, Lindfors P et al. (2014) Long-term follow-up of internet-delivered exposure and mindfulness based treatment for irritable bowel syndrome. Behaviour Research and Therapy 49: 58–61. | Duplication of Ljotsson (2011) paper. |
| Ljotsson B, Andreewitch S, Hedman E et al. (2010) Exposure and mindfulness based therapy for irritable bowel syndrome-An open pilot study. [References]. Journal of Behavior Therapy and Experimental Psychiatry 41: 185–90. | Study type does not match that specified in protocol: Not RCT, before and after study. |
| Ljotsson B, Falk L, Vesterlund AW et al. (2010) Internet-delivered exposure and mindfulness based therapy for irritable bowel syndrome - A randomized controlled trial. [References]. Behaviour Research and Therapy 48: 531–9. | Duplication of Ljotsson (2010) paper. |
| Ljtsson B, Falk L, Hedman E et al. (2011) Internet-delivered cognitive behavior therapy for irritable bowel syndrome - A randomized controlled trial [conference abstract]. Gastroenterology [abstracts from Digestive Disease Week, DDW 2011 Chicago, IL United States.May 7–10] 140 | Incorrect publication type Abstract only. |
| Lowen MB, Mayer EA, Sjoberg M et al. (2013) Effect of hypnotherapy and educational intervention on brain response to visceral stimulus in the irritable bowel syndrome. Alimentary Pharmacology & Therapeutics 37: 1184–97. | Intervention does not match that specified in protocol: Hypnotherapy |
| Mahvi-Shirazi M, Fathi-Ashtiani A, Rasoolzade-Tabatabaei S-K et al. (2012) Irritable bowel syndrome treatment: Cognitive behavioral therapy versus medical treatment. Archives of Medical Science 8: 123–9. | Intervention does not match that specified in protocol: CBT only (not CCBT) |
| McCrone P, Knapp M, Kennedy T et al. (2008) Cost-effectiveness of cognitive behaviour therapy in addition to mebeverine for irritable bowel syndrome. European Journal of Gastroenterology & Hepatology 20: 255–63. | Intervention does not match that specified in protocol: CBT only (not CCBT) |
| Moser G, Dejaco C, Fuhrer M et al. (2012) Gut-focused group hypnosis for treatment of irritable bowel syndrome - A randomised controlled trial. Journal of psychosomatic research [abstracts of the 15th annual meeting of the european association for consultation-liaison psychiatry and psychosomatics, EACLPP and 29th european conference on psychosomatic research, ecpr.2012 jun 27–30; aarhus denmark 72: 494–5. | Intervention does not match that specified in protocol: Hypnotherapy |
| Moser G, Tragner S, Gajowniczek EE et al. (2013) Long-term success of GUT-directed group hypnosis for patients with refractory irritable bowel syndrome: a randomized controlled trial. American Journal of Gastroenterology 108: 602–9. | Intervention does not match that specified in protocol: Hypnotherapy |
| Moss-Morris R, McAlpine L, Didsbury LP et al. (2010) A randomized controlled trial of a cognitive behavioural therapy-based self-management intervention for irritable bowel syndrome in primary care. Psychological Medicine 40: 85–94. | Intervention does not match that specified in protocol: |
| Reme SE, Kennedy T, Jones R et al. (2010) Predictors of treatment outcome after cognitive behavior therapy and antispasmodic treatment for patients with irritable bowel syndrome in primary care.[Erratum appears in J Psychosom Res. 2010 Nov;69(5):523]. Journal of Psychosomatic Research 68: 385–8. | Study type does not match that specified in protocol: Not a comparative study. |
| Reme SE, Stahl D, Kennedy T et al. (2011) Mediators of change in cognitive behaviour therapy and mebeverine for irritable bowel syndrome. Psychological Medicine 41: 2669–79. | Study type does not match that specified in protocol: Not a comparative study. |
| Reme SE, Kennedy T, Jones R et al. (2010) “Predictors of treatment outcome after cognitive behavior therapy and antispasmodic treatment for patients with irritable bowel syndrome in primary care”: Erratum. Journal of Psychosomatic Research 69: 523. | Incorrect publication type: Erratum of Reme (2010) |
| Roberts L, Wilson S, Singh S et al. (2006) Gut-directed hypnotherapy for irritable bowel syndrome: piloting a primary care-based randomised controlled trial. British Journal of General Practice 56: 115–21. | Intervention does not match that specified in protocol: Hypnotherapy |
| Schoultz M, Atherton IM, Hubbard G et al. (2013) The use of mindfulness-based cognitive therapy for improving quality of life for inflammatory bowel disease patients: study protocol for a pilot randomised controlled trial with embedded process evaluation. Trials [Electronic Resource] 14: 431. | Population does not match that specified in protocol: IBD patients, not IBS patients. |
| Tonkin-Crine S, Bishop FL, Ellis M et al. (2013) Exploring patients’ views of a cognitive behavioral therapy-based website for the self-management of irritable bowel syndrome symptoms. Journal of Medical Internet Research 15: e190. | Study type does not match that specified in protocol: Not RCT, qualitative study on patients’ views. |
| Webb AN, Kukuruzovic RH, Catto-Smith AG et al. (2007) Hypnotherapy for treatment of irritable bowel syndrome. [Review] [49 refs]. Cochrane Database of Systematic Reviews : CD005110. | Intervention does not match that specified in protocol: Hypnotherapy |
| Weinland SR, Morris CB, Dalton C et al. (2010) Cognitive factors affect treatment response to medical and psychological treatments in functional bowel disorders. American Journal of Gastroenterology 105: 1397–406. | Not relevant. |
| Whitehead WE (2006) Hypnosis for irritable bowel syndrome: The empirical evidence of therapeutic effects. [References]. International Journal of Clinical and Experimental Hypnosis 54: 7–20. | Intervention does not match that specified in protocol: Hypnotherapy |
| Wilson S, Maddison T, Roberts L et al. (2006) Systematic review: the effectiveness of hypnotherapy in the management of irritable bowel syndrome. [Review] [50 refs]. Alimentary Pharmacology & Therapeutics 24: 769–80. | Intervention does not match that specified in protocol: Hypnotherapy |
| Zijdenbos IL, de Wit NJ, van der Heijden GJ et al. (2009) Psychological treatments for the management of irritable bowel syndrome. [Review] [111 refs]. Cochrane Database of Systematic Reviews : CD006442. | Systematic review/ meta-analysis did not match protocol: Included other interventions that were not covered by the update remit |
| Zomorodi S, Abdi S, Tabatabaee SKR (2014) Comparison of long-term effects of cognitive-behavioral therapy versus mindfulness-based therapy on reduction of symptoms among patients suffering from irritable bowel syndrome. Gastroenterology and Hepatology from Bed to Bench.7 (2) (pp 118–124), 2014.Date of Publication: 2014. | Population does not match that specified in protocol: population used healthy population. |
F.9. Review question 5b (CCBT and mindfulness therapy), economic studies
| Reference | Reason for exclusion |
|---|---|
| Andersson E, Ljotsson B, Smit F et al. (2011) Cost-effectiveness of internet-based cognitive behavior therapy for irritable bowel syndrome: results from a randomized controlled trial. BMC Public Health 11: 215. | Not sufficiently applicable to this guideline: setting for trial and costs is Sweden; perspective is societal; health effects not expressed as QALYs |
| Ljotsson B, Andersson G, Andersson E et al. (2011) Acceptability, effectiveness, and cost-effectiveness of internet-based exposure treatment for irritable bowel syndrome in a clinical sample: a randomized controlled trial. BMC Gastroenterology 11: 110. | Not sufficiently applicable to this guideline: setting for trial and costs is Sweden; perspective is societal; health effects not expressed as QALYs |
- Review question 1 (antidepressants)
- Review question 1 (antidepressants), economic studies
- Review question 2 (low FODMAP diet)
- Review question 3 (linaclotide)
- Review question 4 (lubiprostone)
- Review question 5a (relaxation therapy)
- Review question 5a (relaxation therapies), economic studies
- Review question 5b (CCBT and Mindfulness therapy)
- Review question 5b (CCBT and mindfulness therapy), economic studies
- Excluded studies - Addendum to NICE guideline CG61, Irritable bowel syndrome in ...Excluded studies - Addendum to NICE guideline CG61, Irritable bowel syndrome in adults
Your browsing activity is empty.
Activity recording is turned off.
See more...